Molecular mediators of hepatic steatosis and liver injury
- PMID: 15254578
- PMCID: PMC449757
- DOI: 10.1172/JCI22422
Molecular mediators of hepatic steatosis and liver injury
Abstract
Obesity and its associated comorbidities are among the most prevalent and challenging conditions confronting the medical profession in the 21st century. A major metabolic consequence of obesity is insulin resistance, which is strongly associated with the deposition of triglycerides in the liver. Hepatic steatosis can either be a benign, noninflammatory condition that appears to have no adverse sequelae or can be associated with steatohepatitis: a condition that can result in end-stage liver disease, accounting for up to 14% of liver transplants in the US. Here we highlight recent advances in our understanding of the molecular events contributing to hepatic steatosis and nonalcoholic steatohepatitis.
Figures
Similar articles
-
[Patomechanisms of hepatic steatosis].Orv Hetil. 2010 Feb 28;151(9):323-9. doi: 10.1556/OH.2010.28816. Orv Hetil. 2010. PMID: 20159747 Review. Hungarian.
-
Alpha-lipoic acid decreases hepatic lipogenesis through adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways.Hepatology. 2008 Nov;48(5):1477-86. doi: 10.1002/hep.22496. Hepatology. 2008. PMID: 18972440
-
Is the slippery slope from steatosis to steatohepatitis paved with triglyceride or cholesterol?Cell Metab. 2006 Sep;4(3):179-81. doi: 10.1016/j.cmet.2006.08.010. Cell Metab. 2006. PMID: 16950134 Review.
-
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.Hepatology. 2007 Jun;45(6):1366-74. doi: 10.1002/hep.21655. Hepatology. 2007. PMID: 17476695
-
Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease.Am J Physiol Gastrointest Liver Physiol. 2014 Feb 15;306(4):G320-7. doi: 10.1152/ajpgi.00181.2013. Epub 2013 Dec 19. Am J Physiol Gastrointest Liver Physiol. 2014. PMID: 24356885
Cited by
-
MYC: there is more to it than cancer.Front Cell Dev Biol. 2024 Mar 6;12:1342872. doi: 10.3389/fcell.2024.1342872. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 38510176 Free PMC article. Review.
-
DGAT2 inhibition blocks SREBP-1 cleavage and improves hepatic steatosis by increasing phosphatidylethanolamine in the ER.Cell Metab. 2024 Mar 5;36(3):617-629.e7. doi: 10.1016/j.cmet.2024.01.011. Epub 2024 Feb 9. Cell Metab. 2024. PMID: 38340721 Free PMC article.
-
Modified Buyang Huanwu Decoction alleviates diabetic liver injury via inhibiting oxidative stress in db/db mice.Am J Transl Res. 2024 Jan 15;16(1):39-50. eCollection 2024. Am J Transl Res. 2024. PMID: 38322549 Free PMC article.
-
Hydroalcoholic extract from Sechium edule (Jacq.) S.w. root reverses oleic acid-induced steatosis and insulin resistance in vitro.Heliyon. 2024 Jan 17;10(2):e24567. doi: 10.1016/j.heliyon.2024.e24567. eCollection 2024 Jan 30. Heliyon. 2024. PMID: 38312619 Free PMC article.
-
Hepatic glucose metabolism in the steatotic liver.Nat Rev Gastroenterol Hepatol. 2024 Feb 2. doi: 10.1038/s41575-023-00888-8. Online ahead of print. Nat Rev Gastroenterol Hepatol. 2024. PMID: 38308003 Review.
References
-
- Neuschwander-Tetri B, Caldwell S. Nonalcoholic steatohepatitis:summary of an AASLD single topic conference. Hepatology. 2003;37:1202–1219. - PubMed
-
- Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am. J. Gastroenterol. 2003;98:960–967. - PubMed
-
- Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002;346:1221–1231. - PubMed
-
- Marchesini G, et al. Nonalcoholic fatty liver disease a feature of the metabolic syndrome. Diabetes. 2001;50:1844–1850. - PubMed
-
- Day CP, James OFW. Steatohepatitis: a tale of two “hits”? Gastroenterology. 1998;114:842–845. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
